ARCA biopharma, Inc. and Dr. Michael Bristow, President, Chief Executive Officer and a member of the board of directors of ARCA have mutually agreed to conclude Dr. Bristow's employment and service as a director, effective April 3, 2024. In connection with Dr. Bristow's separation, ARCA and Dr. Bristow entered into a separation agreement on April 3, 2024.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
3.44 USD | -3.91% | -0.29% | +102.35% |
Apr. 25 | ARCA biopharma, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Apr. 19 | North American Morning Briefing : Stock Futures -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
+102.35% | 51.91M | |
-2.88% | 103B | |
+1.38% | 95.28B | |
+1.46% | 22.15B | |
-16.53% | 21.02B | |
-8.58% | 18.15B | |
-38.74% | 16.73B | |
-13.20% | 16.05B | |
+5.49% | 13.68B | |
+33.58% | 12.17B |
- Stock Market
- Equities
- ABIO Stock
- News ARCA biopharma, Inc.
- ARCA biopharma, Inc. Announces Separation of Michael Bristow, Chief Executive Officer